These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Immune and nonimmune effector functions of IgG3 mouse monoclonal antibody R24 detecting the disialoganglioside GD3 on the surface of melanoma cells. Welt S; Carswell EA; Vogel CW; Oettgen HF; Old LJ Clin Immunol Immunopathol; 1987 Nov; 45(2):214-29. PubMed ID: 3665201 [TBL] [Abstract][Full Text] [Related]
4. Pre-clinical models for immunotherapy of melanoma. Reisfeld RA Prog Clin Biol Res; 1989; 288():183-93. PubMed ID: 2654950 [No Abstract] [Full Text] [Related]
5. Melanoma-associated antigens: prospects for clinical use. Lejeune FJ; Libert A Eur J Cancer Clin Oncol; 1985 Dec; 21(12):1433-8. PubMed ID: 3830723 [No Abstract] [Full Text] [Related]
6. Melanoma antibodies: specificity and interaction with melanoma and cytotoxic T-cells. Dippold WG; Knuth A; Meyer zum Büschenfelde KH Behring Inst Mitt; 1984 May; (74):14-8. PubMed ID: 6332614 [TBL] [Abstract][Full Text] [Related]
7. Response to monoclonal antibodies in melanoma: specific or non-specific? Knuth A Eur J Cancer Clin Oncol; 1986 Nov; 22(11):1285-8. PubMed ID: 3830212 [No Abstract] [Full Text] [Related]
8. Ipilimumab, a human monoclonal antibody for treatment of unresectable or metastatic melanoma. Wilkes GM Oncology (Williston Park); 2011 Jul; 25(7 Suppl Nurse Ed):46-7. PubMed ID: 25373277 [No Abstract] [Full Text] [Related]
9. [Treatment of metastatic melanoma with CTLA4 antibodies]. Hafner C Hautarzt; 2010 Sep; 61(9):808-10. PubMed ID: 20721523 [No Abstract] [Full Text] [Related]
10. Cell surface reactive human monoclonal antibody directed to human melanoma-associated gangliosides. Abdel-Wahab Z; Li WP; Darrow T; Nudelman ED; Towell A; Seigler HF Melanoma Res; 1993 Dec; 3(6):415-23. PubMed ID: 8161881 [TBL] [Abstract][Full Text] [Related]
15. Are we entering a new era in melanoma treatment? Lesson from ASCO 2011. Mouawad R; Spano JP; Khayat D Melanoma Res; 2011 Oct; 21(5):377-9. PubMed ID: 21900791 [No Abstract] [Full Text] [Related]
16. Improved melanoma survival at last! Ipilimumab and a paradigm shift for immunotherapy. Gajewski TF Pigment Cell Melanoma Res; 2010 Oct; 23(5):580-1. PubMed ID: 20609175 [No Abstract] [Full Text] [Related]
17. The idiotype (Id) cascade in mice elicited the production of anti-R24 Id and anti-anti-Id monoclonal antibodies with antitumor and protective activity against human melanoma. Ramos AS; Parise CB; Travassos LR; Han SW; de Campos-Lima PO; de Moraes JZ Cancer Sci; 2011 Jan; 102(1):64-70. PubMed ID: 21070480 [TBL] [Abstract][Full Text] [Related]
18. Analysis of therapeutic and immunologic effects of R(24) anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma. Kirkwood JM; Mascari RA; Edington HD; Rabkin MS; Day RS; Whiteside TL; Vlock DR; Shipe-Spotloe JM Cancer; 2000 Jun; 88(12):2693-702. PubMed ID: 10870051 [TBL] [Abstract][Full Text] [Related]
19. Interleukin-2 in the treatment of renal cell carcinoma and malignant melanoma. Eklund JW; Kuzel TM Cancer Treat Res; 2005; 126():263-87. PubMed ID: 16209070 [No Abstract] [Full Text] [Related]